Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 11101 - 11125 of 11481 in total
NDX-3315 is an investigational radiopharmaceutical agent for the diagnosis, treatment monitoring, and management of eosinophilic esophagitis. It is a technetium-99m radiolabeled heparin.
Investigational
Matched Description: … It is a technetium-99m radiolabeled [heparin]. …
Eprotirome which is a compound with promising properties for treatment of obesity and dyslipidemia. Eprotirome increases the body’s energy consumption and reduces body weight and markedly reduces blood lipids and blood glucose.
Investigational
Matched Description: … Eprotirome which is a compound with promising properties for treatment of obesity and dyslipidemia. …
Pradofloxacin is a 3rd generation fluoroquinolone antibiotic developed by Bayer HealthCare AG, Animal Health GmBH. It was approved by the European Commission in April 2011 for bacterial infections in dogs and cats.
Vet approved
Matched Description: … Pradofloxacin is a 3rd generation fluoroquinolone antibiotic developed by Bayer HealthCare AG, Animal …
GS-6620 is under investigation in clinical trial NCT01316237 (A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection).
Investigational
Matched Description: … GS-6620 is under investigation in clinical trial NCT01316237 (A Study Evaluating the Safety, Tolerability …
JNJ-54175446 is under investigation in clinical trial NCT02933762 (A Study in Healthy Participants to Evaluate the Effect of JNJ-54175446 on Amyloid Biomarkers and Cytokine Profiles in Cerebrospinal Fluid and Plasma).
Investigational
Matched Description: … JNJ-54175446 is under investigation in clinical trial NCT02933762 (A Study in Healthy Participants to …
SEA-CD70 is an investigational humanized, non-fucosylated monoclonal antibody targeting CD70. SEA-CD70 is under investigation in clinical trial NCT04227847 (A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies).
Investigational
Matched Description: … SEA-CD70 is under investigation in clinical trial NCT04227847 (A Safety Study of SEA-CD70 in Patients …
Daledin (UK-3557-15) is a selective norepinephrine reuptake inhibitor. It has no effects on the reuptake of serotonin or dopamine, and no antihistamine or anticholinergic properties. It was in trials for depression in the 1970s but never marketed.
Experimental
Matched Description: … Daledin (UK-3557-15) is a selective norepinephrine reuptake inhibitor. …
Talacotuzumab is an IgG1 monoclonal antibody directed toward the IL3 receptor α–subunit, also known as CD123. It is under investigation in clinical trial NCT01632852 (A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission).
Investigational
Matched Description: … It is under investigation in clinical trial NCT01632852 (A Study of CSL362 in Patients With CD123+ Acute …
Sovleplenib is a novel, investigational, selective small molecule inhibitor for oral administration targeting spleen tyrosine kinase (Syk). It is under investigation in clinical trial NCT03483948 (Phase I Study of Hmpl-523+azacitidine in Elderly Patients With Acute Myeloid Leukemia).
Investigational
Matched Description: … Sovleplenib is a novel, investigational, selective small molecule inhibitor for oral administration targeting …
BPN-14770 is under investigation in clinical trial NCT02840279 (A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects).
Investigational
Matched Description: … BPN-14770 is under investigation in clinical trial NCT02840279 (A Multiple Ascending Dose Study of BPN14770 …
Fosifloxuridine nafalbenamide is under investigation in clinical trial NCT03428958 (A Safety Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment).
Investigational
Matched Description: … Fosifloxuridine nafalbenamide is under investigation in clinical trial NCT03428958 (A Safety Study of …
Seltorexant is under investigation in clinical trial NCT03494907 (A Study to Evaluate the Effects of Single-dose Seltorexant on Electrocardiogram Intervals in Healthy Adult Participants).
Investigational
Matched Description: … Seltorexant is under investigation in clinical trial NCT03494907 (A Study to Evaluate the Effects of …
MK-1064 is under investigation in clinical trial NCT02549014 (A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of MK-1064 (MK-1064-001)).
Investigational
Matched Description: … MK-1064 is under investigation in clinical trial NCT02549014 (A Single Dose Study of the Safety, Pharmacokinetics …
LB-100 is under investigation in clinical trial NCT03886662 (A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)).
Investigational
Matched Description: … LB-100 is under investigation in clinical trial NCT03886662 (A Study of LB-100 in Patients With Low or …
Carotegrast methyl is under investigation in clinical trial NCT03531892 (A Study to Evaluate the Safety and Efficacy of AJM300 in Participants With Active Ulcerative Colitis).
Investigational
Matched Description: … Carotegrast methyl is under investigation in clinical trial NCT03531892 (A Study to Evaluate the Safety …
CXD101 is under investigation in clinical trial NCT03873025 (A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-cell Lymphoma).
Investigational
Matched Description: … CXD101 is under investigation in clinical trial NCT03873025 (A Study of CXD101 in Combination With Pembrolizumab …
mRNA-3351 is a modified mRNA encoding the UGT1A1 gene. Developed by Moderna, it is currently being investigated as the treatment for Crigler-Najjar syndrome
Experimental
Matched Description: … mRNA-3351 is a modified mRNA encoding the UGT1A1 gene. …
Dalosirvat is under investigation in clinical trial NCT03742518 (A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia).
Investigational
Matched Description: … Dalosirvat is under investigation in clinical trial NCT03742518 (A Study Evaluating the Efficacy and …
Egaptivon pegol, formerly known as ARC1779, is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF), the ligand for receptor glycoprotein 1b on platelets. Egaptivon pegol is being investigated for the treatment of thrombotic thrombocytopenic purpura and acute coronary syndromes.[A3290, A259053] Egaptivon pegol is a therapeutic...
Investigational
Matched Description: … Egaptivon pegol, formerly known as ARC1779, is a therapeutic aptamer antagonist of the A1 domain of von ... [A3290, A259053] Egaptivon pegol is a therapeutic oligonucleotide ("aptamer") which blocks the binding …
PH-284 belongs to a new family of new chemical entities called vomeropherins. Vomeropherins are self-administered by the patient with a metered nasal spray, or nasal aerosol device so that they can bind to peripheral chemosensory receptors in the nasal passages. This binding produces neural impulses that are transmitted by specific...
Investigational
Matched Description: … PH-284 belongs to a new family of new chemical entities called vomeropherins. ... Vomeropherins are self-administered by the patient with a metered nasal spray, or nasal aerosol device …
DTS-201 is a prodrug of doxorubicin, a widely used anti-cancer drug that Diatos intends to develop for the treatment of various solid tumors. It is activated in the tumor environment. DTS-201 may be suitable for the treatment of many types of solid tumors, including tumors sensitive to doxorubicin and potentially...
Investigational
Matched Description: … DTS-201 is a prodrug of doxorubicin, a widely used anti-cancer drug that Diatos intends to develop for …
Synephrine, also referred to as, p-synephrine, is naturally occurring alkaloid. It is present in approved drug products as neo-synephrine, its m-substituted analog. p-synephrine and m-synephrine are known for their longer acting adrenergic effects compared to norepinephrine. The similarity of naming between m-synephrine and the unsubstituted form, synephrine, is a source...
Experimental
Matched Description: … The similarity of naming between m-synephrine and the unsubstituted form, synephrine, is a source of ... some confusion however m-synephrine refers to a related drug more commonly known as phenylephrine. …
Virus Specific T-Cells (VSTs) are a target therapy that are generated for specific viral antigens. These products are generated from virus-naive or virus-experienced autologous or allogenic sources. Antigens identified as an immune target are presented by antigen-presenting cells (APCs) to T-cells along with other molecules that stimulate their growth and...
Investigational
Matched Description: … Virus Specific T-Cells (VSTs) are a target therapy that are generated for specific viral antigens. ... These T-cells are then isolated from the donor and expanded in a culture to generate more VSTs. …
PI-166 is a small organic compound with specific avidity to liver cancer cells. It has demonstrated the ability to reduce the growth of rat hepatomas, which is like human hepatomas, are resistant to established anti-cancer agents.
Investigational
Matched Description: … PI-166 is a small organic compound with specific avidity to liver cancer cells. …
SLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the cannabinoid type 1 (CB1) receptor. It is developed for the treatment of obesity and other metabolic disorders.
Investigational
Matched Description: … SLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the cannabinoid …
Displaying drugs 11101 - 11125 of 11481 in total